Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study

This report has been verified by one or more authors of the original publication.

Following a 7-10 day open label run-in phase which studied the safety and efficacy of prophylaxis with semuloparin, 469 patients were randomized in a 2:1 ratio to a 19-23-day long treatment of either semuloparin or a placebo in a double blind phase. 23 days after the end of treatment, the semuloparin group had a 79% relative risk reduction in the rate of any venous thromboembolism or all-cause death. It also had the same treatment emergent adverse event profile as the placebo with only 2 clinically relevant bleedings, no thrombocytopenia, or liver injuries.